ReviewPharmacological reports : PR2024
Mechanistic insights on TLR-4 mediated inflammatory pathway in neurodegenerative diseases.
Review in Pharmacological reports : PR, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- ProbioticGut microbes · 2026Article
- Triangulating the Neuroprotective Mechanisms of Pterostilbene in Hyperhomocysteinemia Induced Cognitive Impairment: Insights from In Silico, Proteomics, and Experimental Validation.Neuromolecular medicine · 2026Article
- Cinnamon and Derivatives as Modulators of Toll-like Receptors.International journal of molecular sciences · 2026Review
- Elucidating the Protective Potential of Ferulic Acid Against Sodium Arsenite- Induced Thyroid and Adrenal Toxicity: An Integrated In-Silico Molecular Docking and In-Vivo Experimental Approach.Biological trace element research · 2026Article
- Therapeutic potential of apigenin in neurodegenerative diseases and brain health.Molecular biology reports · 2026Review
- Targeting the SIRT1-TLR4 axis attenuates oxidative inflammation in a cellular model of bronchopulmonary dysplasia.Pediatric research · 2026Article
- Lanzhou Lily (Food science & nutrition · 2026Article
- Bridging neuroinflammation, oxidative stress, and neurogenesis: aromatic turmerone as a multifunctional modulator via NF-κB and Nrf2 pathways.Inflammopharmacology · 2026Review
- Lactobacillus Reuteri L81 Alleviates Intestinal Barrier Damage Induced by Escherichia Coli K99 in Mice by Modulating Gut Microbiota Composition and Metabolic Products.Probiotics and antimicrobial proteins · 2026Article
- Unknotting the crosstalk between COPD and neuroinflammation.Journal of neuroinflammation · 2026Review
- Optimization of THP-1-CAR monocytes utilizing CD32a signaling phagocytosis for antigen-specific T cell activation.Scientific reports · 2026Article
- CircFRRS1 drives neuroinflammation through the miR-27a-3p/TLR4 pathway after deep hypothermic circulatory arrest.Frontiers in cellular neuroscience · 2026Article
- DEHP induces stress urinary incontinence by causing urethral sphincter dysfunction via inflammation and apoptosis: a mechanism study based on animal experiments, network toxicology, and molecular docking.Frontiers in cell and developmental biology · 2026Article
- Targeting Cardiotoxicity Induced by Environmental Toxins: The Role of Natural Products.Cardiovascular toxicology · 2025Review
- Age-Related Changes in Neuroinflammation and Epigenetic Regulation in Mouse Ischemic Stroke Model.Brain sciences · 2025Article
- Therapeutic potential of COX-2 inhibitors in neuropsychiatric disorders.Journal of neural transmission (Vienna, Austria : 1996) · 2025Review
- Targeting NOX inhibitors in neurodegeneration: a therapeutic perspective.Metabolic brain disease · 2025Review
- Targeting hypoxia-related pathobiology in Alzheimer's disease: strategies for prevention and treatment.Molecular biology reports · 2025Review
- A Novel Frontier in Gut-Brain Axis Research: The Transplantation of Fecal Microbiota in Neurodegenerative Disorders.Biomedicines · 2025Review
- Ferroptosis and Alzheimer's: unveiling new avenues for the treatment and prevention.Metabolic brain disease · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurodegenerative diseases (NDDs) pose a significant issue in healthcare, needing a thorough knowledge of their complex molecular mechanisms. A diverse set of cell signaling mediators and their interactions play critical roles in neuroinflammation. The release of pro-inflammatory mediators in response to neural dysfunction is detrimental to normal cell survival. Moreover, the important role of nuclear factor-κB (NF-κB) in the central nervous system through Toll-like receptor (TLR) activation has been well established. Therefore, through a comprehensive review of current research and experimentation, this investigation elucidates the interactions between novel pharmacological agents (TLR-4/NF-κB inhibitors) and neurodegeneration encompassing Alzheimer's, Parkinson's, Huntington's disease, amyotrophic lateral sclerosis and stroke. Insights garnered from this exploration underscore the potential of TLR-4 as a therapeutic target. Through the revelation of these insights, our aim is to establish a foundation for the development of enhanced and focused therapeutic approaches in the continuous endeavor to combat neurodegeneration. This review thus serves as a roadmap, guiding future research endeavors toward innovative strategies for combatting the complex interplay between TLR-4 signaling and NDDs.
Indexed as
Identifiers
38918327What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.